GLP-1 follow-up and lab monitoring: questions to ask before starting

Follow-up is part of the product you are buying

A GLP-1 program is not just an intake form and a medication shipment. Compare how each provider checks in after the first visit, who reviews symptoms, how dose changes are handled, and what happens when a question does not fit inside a routine message thread.

Ask about early follow-up cadence

The Endocrine Society obesity pharmacotherapy guideline recommends assessing efficacy and safety at least monthly for the first three months, then at least every three months for patients prescribed weight-loss medications. A provider does not need to use that exact schedule for every patient, but vague follow-up language is a signal to ask more questions.

• How soon after the first prescription will a licensed clinician check in?
• Who decides whether to continue, pause, or adjust a medication discussion?
• What symptoms should trigger a same-day response instead of the next scheduled visit?
• How are missed visits, refill timing, and delayed lab results handled?

Separate routine labs from individual-risk monitoring

There is no single lab checklist that fits every person. A credible clinic should explain which labs, vital signs, medication history, pregnancy considerations, diabetes history, kidney concerns, and other factors apply to your situation before presenting monitoring as a generic package.

Know which symptoms need escalation

FDA-approved GLP-1 labels discuss warnings that may include severe gastrointestinal reactions, pancreatitis, gallbladder disease, kidney injury related to dehydration, hypoglycemia risk when combined with some diabetes medicines, allergic reactions, vision changes in people with diabetes, and anesthesia or deep-sedation considerations. Ask the care team to translate those warnings into a written escalation plan for you.

• What symptoms mean I should contact the clinic quickly?
• What symptoms mean I should seek urgent or emergency care locally?
• How should I handle vomiting, diarrhea, dehydration concerns, or low-blood-sugar symptoms?
• Who should I tell if I have a planned surgery, dental procedure, or anesthesia appointment?

Dose changes should be explained, not automatic

GLP-1 medication labels and clinical practice commonly involve gradual dose changes, but timing and tolerability matter. Ask whether dose changes are based on a clinician review of side effects, treatment response, other medications, and your goals rather than a fixed calendar alone.

Use side-effect reporting as a trust signal

FDA MedWatch accepts reports from patients, consumers, and health professionals for serious adverse events, product-quality concerns, use errors, and therapeutic failures. A strong provider should tell you how to report concerns to the care team, when FDA reporting may be appropriate, and how medication or pharmacy problems are documented.

What a written follow-up plan should include

Before paying for a program, ask for a plain-language follow-up plan: visit cadence, clinician role, expected monitoring, side-effect instructions, refill process, pharmacy contact path, insurance or cash-pay changes, and the local-care situations the online program cannot manage.